Progressive supranuclear palsy: Disease profile and rehabilitation strategies

Physical Therapy

Volumn 86, Issue 6, 2006, Pages 870-880

  Zampieri, Cris ^a   Di Fabio, Richard P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Fall prevention; Gaze control; Progressive supranuclear palsy; Rehabilitation; Visual attention

Indexed keywords

ANTIDEPRESSANT AGENT; BOTULINUM TOXIN; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

BLEPHAROSPASM; CLINICAL EXAMINATION; CLINICAL FEATURE; DEPRESSION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DYSARTHRIA; DYSPHAGIA; EYE MOVEMENT; GAIT; HISTORY OF MEDICINE; HUMAN; INCIDENCE; LABORATORY TEST; NEUROPATHOLOGY; PALLIATIVE THERAPY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHYSIOTHERAPIST; PHYSIOTHERAPY; PREVALENCE; PROGNOSIS; PROGRESSIVE SUPRANUCLEAR PALSY; REHABILITATION; REVIEW; SPEECH THERAPY; TRAINING;

EID: 33744826794     PISSN: 00319023     EISSN: None     Source Type: Journal    
DOI: 10.1093/ptj/86.6.870     Document Type: Review

References (76)

1. Litvan I. Diagnosis and management of progressive supranuclear palsy. Semin Neurol. 2001;21:41-48.
2. Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996;46:922-930.
3. Schag A, Ben-Shlomo Y, Quinn BNP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999;354:1771-1775.
4. Litvan I. Update on progressive supranuclear palsy. Current Neurology and Neuroscience Reports. 2004;4:296-302.
5. Burn DJ, Lees AJ. Progressive supranuclear palsy: where are we now? Lancet. 2002;1:359-369.
6. Litvan I, Campbell G, Mangone CA, et al. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain. 1997;120:65-74.
7. Tolosa E, Valldeoriola F, Marti MJ. Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). J Neural Transm. 1994;42(suppl):15-31.
8. Duvoisin RC. Differential diagnosis of PSP. J Neural Transm. 1994; 42(suppl):51-67.
9. Steele J, Richardson J, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333-359.
10. Nath U, Ben-Shlomo Y, Thomson RG, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain. 2001;124:1438-1449.
11. Chiò A, Magnani C, Schiffer D. Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord. 1998;13:400-405.
12. Rijk MC, Breteler MMB, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam study. Neurology. 1995;45: 2143-2146.
13. Wewrmuth L, Joensen P, Bunger N, Jeune B. High prevalence of Parkinson's disease in the Faroe Islands. Neurology. 1997;49:426-432.
14. Golbe GI, Davis PH, Shoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology. 1988;38: 1031-1034.
15. Bower JH, Marangore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology. 1997;49:1284-1288.
16. Kristenseri MO. Progressive supranuclear palsy: 20 years later. Acta Neurol Scand. 1985;71:177-189.
17. Nath U, Ben-Shlomo Y, Tomson RG, et al. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology. 2003;60:910-916.
18. Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord. 2002;17:1255-1264.
19. Josephs KA, Dickson DW. Diagnostic accuracy of progressive supranuclear palsy in the society for progressive supranuclear palsy brain bank. Mov Disord. 2003;18:1018-1026.
20. Slegtenhorst MV, Lewis J, Hutton M. The molecular genetics of the tauopathies. Exp Gerontol. 2000;35:461-471.
21. Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1991;21:428-433.
22. Flament S, Delacourte A, Verny M, et al. Abnormal tau protein in progressive supranuclear palsy: similarities and differences with neurofibrillary degeneration of the Alzheimer type. Acta Neuropathol (Berl). 1991;81:591-596.
23. Albers DS, Augood SJ. New insights into progressive supranuclear palsy. Trends Neurosci. 2001;24:347-353.
24. Caparros-Lefebvre D, Elbaz A (Caribbean Parkinsonism Study Group). Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Lancet. 1999;354:281-286.
25. Caparros-Lefebvre D, Sergeant N, Lees A, et al. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain. 2002;125:801-811.
26. Angibaud G, Gaultier C, Rascol O. Atypical parkinsonism and Annonaceae consumption in New Caledonia. Mov Disord. 2004;19:603.
27. Chaudhuri KR, Hu MTM, Brooks DJ. Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK. Mov Disord. 2000;15:18-23.
28. Lannuzel A, Michel PP, Caparros-Lefebvre D, et al. Toxicity of Annonaceae for dopaminergic neurons: potential role in atypical parkinsonism in Guadaloupe. Mov Disord. 2002;17:84-90.
29. Lannuzel A, Michel PP, Höglinger GU, et al. The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. Neuroscience. 2003; 121:287-296.
30. Yoshida M, Niwa T, Nagatsu T. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes. Neurosci Lett. 1990;119:109-113.
31. Langston JW, Forno LS, Tetrud J, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine exposure. Ann Neurol. 1999;46: 598-605.
32. Brown J, Lantos P, Stratton M, et al. Familial progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1993;56:473-476.
33. Golbe LI, Dickson DW. Familial autopsy-proven progressive supranuclear palsy. Neurology. 1995;45(4 suppl):A255.
34. Gazeley S, Maguire JA. Familial progressive supranuclear palsy. Clin Neuropathol. 1996;15:215-220.
35. Morris S, Morris ME, Iansek R. Reliability of measurements obtained with the Timed "Up & Go" Test in people with Parkinson disease. Phys Ther. 2001;81:810-808.
36. Rojo A, Pernaute RS, Fontán A, et al. Clinical genetics of familial progressive supranuclear palsy. Brain. 1999;122:1233-1245.
37. Bonifati V, Joosse M, Nicholl DJ. The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. Neurosci Lett. 1999;274: 61-65.
38. Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol. 1997;41:277-281.
39. Higgins JJ, Golbe L, Biase AD, et al. An extended 5′-tau susceptibility halotype in progressive supranuclear palsy. Neurology. 2000;55: 1364-1367.
40. Higgins JJ, Litvan I, Nee LE, Loveless JM. Mutational analysis of the tau gene in progressive supranuclear palsy. Neurology. 1999;55: 1364-1367.
41. Swerdlow RH, Golbe LI, Parks JK, et al. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J Neurochem. 2000;75:1681-1684.
42. Albers DS, Swerdlow RH, Manfredi G, et al. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp Neurol. 2001;168:196-198.
43. Goetz CG, Leurgans S, Lang AE, Litvan I. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology. 2003;60:917-922.
44. Litvan I, Bhatia KP, Burn DJ, et al. SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord. 2003;18:467-486.
45. Santacruz P, Uttl B, Litvan I, Grafman J. Progressive supranuclear palsy: a survey of the disease course. Neurology. 1998;50:1637-1647.
46. Masucci EF, Kurtzke JF. Tremor in progressive supranuclear palsy. Acta Neurol Scand. 1989;80:196-300.
47. Daniel SE, deBuin VMS, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain. 1995;118:759-770.
48. Nuwer M. Progressive supranuclear palsy despite normal eye movements. Arch Neurol 1981;38:784.
49. Boeve B, Dickson D, Duffy J. Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. Eur Neurol. 2003;49:72-78.
50. Matsuo H, Takashima H, Kishikawa M, et al. Pure akinesia: an atypical manifestation of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1991;54:397-400.
51. Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci. 2003;210:57-60.
52. Savoiardo M. Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci. 2003;24(suppl 1):S35-S37.
53. Yekhlef F, Ballan G, Macia F, et al. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm. 2003;110:151-169.
54. Paviour D, Price S, Stevens J, et al. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology. 2005;64:675-679.
55. Oka M, Katayama S, Imon Y, et al. Abnormal signals on proton density-weighted MRI of the superior cerebellar peduncle in progressive supranuclear palsy. Acta Neurol Scand. 2001;104:1-5.
56. Solomon D. Eye Movement Problems in Progressive Supranuclear Palsy. Hunt Valley, Md: Society for Progressive Supranuclear Palsy; 2005.
57. Cubo E, Stebbins GT, Golbe LI, et al. Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord. 2000;15:276-279.
58. Golbe LI. A clinical rating scale and staging system for progressive supranuclear palsy. Neurology. 1997;48:A326.
59. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol. 1993; 16:338-346.
60. Kompoliti K, Goetz CG, Litvan I, et al. Pharmachological therapy in progressive supranuclear palsy. Arch Neurol. 1998;55:1099-1102.
61. Rascol O, Sieradzan K, Peyro-Saint-Paul H, et al. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Mov Disord. 1998;13:673-676.
62. Weiner WJ, Minagar A, Shulman LM. Pramipesole in progressive supranuclear palsy. Neurology. 1999;52:873-874.
63. Suteerawattananon MB, Neil BM, Protas EJ. Supported treadmill training for gait balance in a patient with progressive supranuclear palsy. Phys Ther. 2002;82:485-495.
64. Sosner J, Wall GC, Sznajder J. Progressive supranuclear palsy: clinical presentation and rehabilitation of two patients. Arch Phys Med Rehabil. 1993;74:537-539.
65. Izzo K, DiLorenzo P, Roth A. Rehabilitation in progressive supranuclear palsy: case report. Arch Phys Med Rehabil. 1986;67:473-476.
66. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
67. Duncan P, Weiner D, Chandler J, Studenski S. Functional reach: a new clinical measure of balance. J Gerontol. 1990;45:M192-M197.
68. Horak F, Nasher L, Nutt J. Postural instability in Parkinson's disease: motor coordination and sensory organization. Neurol Rep. 1988;12:54-55.
69. Berg K, Wood-Dauphinee S, Williams J, Gayton D. Measuring balance in the elderly: preliminary development of an instrument. Physiother Can. 1989;41:304-311.
70. Ondo W, Warrior D, Overby A, et al. Computerized posturography analysis of progressive supranuclear palsy. Arch Neurol. 2000;57: 1464-1469.
71. Patla A. Understanding the role of vision in the control of human locomotion. Gait Posture. 1997;5:54-69.
72. Hollands M, Patla A, Vickers J. "Look where you're going!": gaze behavior associated with maintaining and changing the direction of locomotion. Exp Brain Res. 2002;143:221-230.
73. Di Fabio RP, Zampieri C, Greany JF. Aging and saccade-stepping interactions in humans. Neurosci Lett. 2003;339:179-182.
74. Di Fabio RP, Zampieri C, Henke J, et al. Influence of elderly executive cognitive function on attention in the lower visual field during step initiation. Gerontology. 2005;51:94-107.
75. Di Fabio R, Zampieri C, Tuite P, Knoczak J. Association between vestibulo-ocular reflex suppression during smooth movements of the head and attention deficit in progressive supranuclear palsy. Mov Disord. In press.
76. Di Fabio RP, Zampieri C, Tuite P, Konczak Y. Vertical gaze enhanced with biofeedback for patients with progressive supranuclear palsy: evidence for movement related plasticity in a chronic progressive neurological disorder [abstract]. Mov Disord. 2004;19:1124.